Formosa Pharma and Eyenovia Set to Launch New FDA-Approved Ophthalmic Drug in US
Portfolio Pulse from Benzinga Newsdesk
Formosa Pharma and Eyenovia are set to launch a new FDA-approved ophthalmic drug, APP13007, in the US. The drug, developed using Formosa's APNT® nanotechnology, offers a convenient dosing regimen and targets a $1.3 billion market.
September 09, 2024 | 7:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eyenovia is set to commercialize APP13007, a new FDA-approved ophthalmic drug, in the US. The drug targets a $1.3 billion market and offers a competitive advantage with its convenient dosing regimen.
Eyenovia is directly involved in the commercialization of APP13007, which is expected to capture a significant share of the $1.3 billion ophthalmic market due to its convenient dosing and proven efficacy. This positions Eyenovia for potential revenue growth.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90